NCT05616650招募中2 期
A Phase II Trial of Focal Ultrahypofractionated Stereotactic Radiation Therapy for the Treatment of Unifocal Prostate Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 42
- 试验地点
- 1
- 主要终点
- Pathologic complete response rate
研究概览
简要总结
Background:
The current standard treatment of prostate cancer is either surgery or radiation. Typically, this includes either the removal or radiation of the whole prostate gland. Many people now seek out focal therapy options to decrease the side effects of treatment. Until now, several forms of physical destruction with heat (thermal ablation), cold (cryotherapy), sound waves (HIFU), laser (FLA), and electrical energy (IRE). A new type of radiation (SBRT) may be an effective way to cure men of early-stage prostate cancer with fewer side effects than standard treatments.
Objective:
To see how people with untreated localized prostate cancer will respond to focal therapy with SBRT.
Eligibility:
People aged 18 years and older with untreated localized prostate cancer (prostate cancer which has not spread outside of the prostate gland).
Design:
- Participants will undergo screening including blood tests, an MRI, a PSMA PET/CT (18F-DCFPyL), and a biopsy.
- Small, non-radioactive, gold seeds about the size of a grain of rice will be placed in and/or around the tumor to help target the radiation treatment.
- Radiation (SBRT) will occur in 2 separate sessions about 1 week apart. No sedation is used, these sessions are painless. Each session will take about 1-2 hours. Participants can go home afterwards.
- Follow-up will continue for 2 years with repeat scans (MRI and PSMA PET/CT) and blood (PSA) tests.
- After two years, a biopsy will be done to understand the impact of this new treatment on prostate cancer.
详细描述
Background:
- Prostate cancer is the most common cancer among American men.
- The best current validated treatment options include whole gland radiotherapy and radical prostatectomy.
- Based on recent advances in imaging, focal ablative therapies are under investigation in attempts to deliver comparable rates of tumor control with less side effects.
- Thus far, focal therapies such as cryotherapy, high-intensity focused ultrasound, or focal laser ablation have resulted in poor local control with the exception of implanted radiation sources which have shown in-field control rates > 90%.
- As such, the proposed trial is designed to investigate the efficacy of a novel form of focal stereotactic body radiation therapy (SBRT) for the treatment of localized, unifocal prostate cancer.
- Prostate specific membrane antigen (PSMA) targeted PET imaging was recently FDA approved for imaging men with suspected prostate cancer metastases who are potentially curable by radiation or surgery. 18F-DCFPyL, a second generation PSMA PET agent that binds with high affinity to PSMA yet clears rapidly from the blood pool will be used in this study.
Objective:
-To determine whether localized, tumor-directed SBRT can produce biopsy-confirmed tumor response at 24 months in participants with unifocal prostatic adenocarcinoma.
Eligibility:
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 120 Years（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •INCLUSION CRITERIA:
- •Participants must have histologically confirmed, low or intermediate risk prostatic adenocarcinoma verified by biopsy (NIH Laboratory of Pathology confirmation is required).
- •Unifocal prostate cancer defined as a single focus of prostate cancer on MRI and PSMA PET/CT imaging which is correlated with a positive targeted biopsy.
- •Age >=18 years.
- •ECOG performance status <=2 (Karnofsky >60%).
- •Men must agree to use highly effective contraception with their partner (barrier method of birth control; abstinence) for the duration of study participation and up to 120 days after the last radiation treatment.
- •Ability of individual to understand and the willingness to sign a written informed consent document.
排除标准
- •Participants with NCCN high-risk prostate cancer features (Gleason score >=8, >cT2c, or PSA >= 20 ng/mL).
- •Participants with prostate biopsies which show >= grade group 2 adenocarcinoma determined to be outside of the radiographically visible lesion (systematic biopsies which map to a radiographically detected lesion are not an exclusion criterion).
- •Participants in whom concurrent systemic Androgen Deprivation Therapy (ADT) or chemotherapy is planned.
- •Participants who are receiving any other investigational agents.
- •Participants found to have pelvic or distant metastases on pre-treatment staging studies.
- •Participants with an AUA-SI/IPSS score >
- •Participants who have previously received curative treatment for a prior or the current diagnosis of prostate cancer.
- •Active urinary tract infection assessed by urinalysis.
- •Human immunodeficiency virus (HIV)-infected individuals who are not on effective anti-retroviral therapy. Participants on anti-retroviral therapy with undetectable viral load within the 6 months prior to registration are eligible for this trial.
- •Participants with hepatitis B virus (HBV) infection who have not been treated and cured.
- •Participants with chronic HBV at screening must have an undetectable HBV viral load on suppressive therapy.
- •Participants with hepatitis C virus (HCV) infection who have not been treated and cured.
- •Participants with HCV infection who are currently on treatment, are eligible if they have an undetectable HCV viral load at screening.
- •Anatomic relationship between the tumor and adjacent normal tissues judged to be unfeasible for the planned treatment by the PI.
- •Participants with connective tissue diseases.
- •Participants with radiation hypersensitivity syndromes.
- •Ongoing active inflammatory bowel disease within the radiation field.
- •Participants with prior medical comorbidity or surgical history involving the low pelvis which is expected to confer a high risk of toxicity to the experimental radiation regimen.
- •Ineligibility or unwillingness to undergo a contrast-enhanced MRI due to inadequate renal function (eGFR < 30), severe claustrophobia, a weight above tolerance of the scanner (> 350 lbs.), a body size unable to fit into the scanner, or implanted devices incompatible with an MRI (implanted cardiac devices, surgical hardware, retained shrapnel, cerebral aneurysm clips, or other incompatible objects.
- •Unwillingness to undergo an 18F-DCFPyL PET/CT or known allergy to the 18F-DCFPyL tracer.
- •Contraindication or inability to undergo fiducial marker implantation.
- •History of prior radiotherapy overlapping with the intended radiation field.
- •Uncontrolled intercurrent illness, factors, or social situations that would limit compliance with study requirements.
研究组 & 干预措施
1/Focal SBRT
Experimental
Focal SBRT to the tumor focus within the prostate, with response assessed by biopsy and imaging, including 18F-DCFPyL PET/CT.
干预措施: Stereotactic Body Radiation Therapy (Radiation)
1/Focal SBRT
Experimental
Focal SBRT to the tumor focus within the prostate, with response assessed by biopsy and imaging, including 18F-DCFPyL PET/CT.
干预措施: 18F-DCFPyL (Drug)
结局指标
主要结局
Pathologic complete response rate
时间窗: 2 years
The primary objective of this trial is to determine the pathologic complete response rate on biopsy at two years in patients undergoing focal SBRT for prostate cancer. This will be defined by a negative biopsy at 2 years post-treatment.
次要结局
- Longitudinal quality of life (QoL)(baseline and 1, 3, 6, 9, 12, 15, 18, 21, and 24 months after focal SBRT)
- PSA kinetics(1 week and 1, 3, 6, 9, 12, 15, 18, 21, 24 months after focal SBRT)
- Nadir PSA(1 week and 1, 3, 6, 9, 12, 15, 18, 21, 24 months after focal SBRT)
- Absolute and relative fraction of free PSA to bound PSA(1 week and 1, 3, 6, 9, 12, 15, 18, 21, 24 months after focal SBRT)
- Toxicity profile(During the focal SBRT period and 1, 3, 6, 9, 12, 18, 24 months after focal SBRT)
- Rate of biochemical failure(24 months after focal SBRT)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Short Course Radiotherapy for Localized Prostate CancerAdenocarcinoma of ProstateNCT03518853Tata Medical Center30
进行中（未招募）
不适用
Ultra-hypofractionated Radiation in Prostate CancerEarly Stage Prostate CancerNCT03486821University of Kansas Medical Center13
进行中（未招募）
不适用
A First Step Towards Ultra-hypofractionation for Unfavourable Intermediate and High-risk Prostate CancerProstate CancerNCT05361902Erasmus Medical Center35
招募中
不适用
Observational Study on Extreme Hypofractionation for Localized Prostate CancerRadiotherapySBRTProstate CancerNCT05344235Universitaire Ziekenhuizen KU Leuven246
尚未招募
不适用
HYpofractionated irradiation for PROstate cancerA randomized multicenter phase III study.Prostate cancer has become the most common non-skin malignancy in men in Western countries. Over recent years the number of diagnosed patients has increased dramatically because of routine prostate-specific antigen (PSA) testing. For a large proportion of prostate cancer patients, external-beam radiotherapy (EBRT) will be the treatment of choice.NL-OMON22744Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, Netherlands Cancer Institute, Amsterdam800